Ōura delays Nasdaq listing amid volatile IPO market

Ōura delays Nasdaq listing amid volatile IPO market
Ōura postpones Nasdaq IPO

After moving into the final stages of its planned market debut, Ōura is postponing its Nasdaq initial public offering because of uncertainty in the IPO market. The Finnish-American smart ring maker had been seeking to raise as much as $2.2 billion at a valuation of up to $14 billion after publishing its prospectus in early September.

Highlights

  • Ōura delayed its planned Nasdaq IPO despite strong demand, citing market uncertainty after recent filings indicated a valuation up to $14 billion and $2.2 billion in proceeds.
  • The company published its prospectus in early September and was in the late stages of preparing to go public before pausing the process.
  • Ōura's postponement underscores continued volatility for large tech IPOs, as Wall Street also anticipates Anthropic's potential $2 trillion market debut later this year.

Listing plan pauses after September filings

As reported by Financial Times, Ōura says it is delaying its planned Nasdaq listing even though it sees strong demand for the offering. The company says market uncertainty is driving the decision as it steps back from a flotation that had recently advanced through updated filing documents.

Last week's filing indicated that the health-tracking smart ring maker was targeting proceeds of up to $2.2 billion and a valuation of as much as $14 billion. The company had published its prospectus in early September and had been in the late stages of preparing to go public.

Chief executive Tom Hale says Ōura wants to deliver an extraordinary IPO for employees and investors and has the flexibility to choose its timing. He adds that the company will continue executing on opportunities ahead while the listing is on hold.

IPO delay adds to market watch on tech floats

The postponement comes as Wall Street is also watching for AI company Anthropic's public filing ahead of what could be a $2 trillion IPO later this year. Ōura's decision highlights the uneven backdrop for large technology listings, even when investor demand appears solid.

The move leaves one of the higher-profile consumer health technology flotations waiting for a clearer market window. It also suggests issuers are still weighing valuation ambitions and execution risk carefully before proceeding with major public offerings.

Our earlier coverage of China’s tighter scrutiny of humanoid robot startups seeking IPOs explained how regulators are raising listing standards around sustainable revenue, commercial orders, narrowing losses, and ownership of core technology. We also noted cooling investor sentiment and growing valuation pressure across AI-focused segments, reinforcing that even high-demand stories can face tougher hurdles and timing risks in public markets.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.